Dr. Wesley M. Jose

Dr. Wesley M. Jose

Clinical Professor
MBBS, MD (Internal Medicine), DNB (Medical Oncology), MNAMS, FIACM, PGDIM
Speciality: Cardiac Sciences, Medical Oncology, Amrita Cardio Oncology Clinic
Book an Appointment
Overview
Qualification
Work Experience
Area of Expertise
Investigator
Awards and Recognition
Additional Training

Dr. Wesley M. Jose joined Amrita Institute of Medical Sciences in April 2008. He currently serves as Professor at the Department of Medical Oncology and Hematology at Amrita Institute.
Dr. Wesley did his medical training from Christian Medical College and Hospital, Ludhiana, Punjab. Prior to joining Amrita, he worked as an Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana.
His core research interests lie in Neuro-oncology. He is an academician. He has presented several scientific papers and continues to be an invited faculty for various oncology conferences.
His primary clinical practice areas include: - Breast Cancer, Brain Tumors (Ault and Pediatric), Gastrointestinal malignancies, Multiple Myeloma, Lymphoma and Pediatric solid cancers.

  • Medical Training from Christian Medical College and Hospital, Ludhiana, Punjab  

    ADDITIONAL TRAINING 
  • Equator Network – CONSORT 2010 reporting guidelines - Oxford, UK, 2010. 
  • Randomized Controlled Trials – Oxford, UK, 2010 
  • Statistics for Health Research – Oxford, UK, 2010 
     

Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana .

  • Breast Cancer 
  • Brain Tumors (Ault and Pediatric) 
  • Gastrointestinal malignancies 
  • Multiple Myeloma 
  • Lymphoma and Pediatric solid cancers
  • RI-02-003

    Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukaemia (CLL) in Routine Clinical Practice

  • LRP/LNP3794/2016/006

    A Phase II/III Pivotal, Open-label, Randomized, 3 Arm Study to Assess the Efficacy of Lupin’s Molecule Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer as Second Line Therapy

  • CLDK378A2301

    A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Protocol No. 476-13

    A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Protocol No. - CDP/03/07

    "A randomized, multi-center, open label study to evaluate the efficacy and safety of Peg G-CSF as compared to Grafeel® in the prophylaxis of severe neutropenia in cancer patients receiving cytotoxic chemotherapy". (Sponsor: Dr. Reddy's Laboratories).

  • Protocol No. - MK-0683-088

    "An international, Multi-center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma". (Sponsor: Merck & Co Inc.)

  • Protocol No. - MORAb-003-004

    "A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety Weekly Farletuzmab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum sensitive Ovarian Cancer in First Relapse" (Sponsor: Morphotek Inc.).

  • Protocol No: EGF 110656

    "A Phase III Study of ERBB2 Positive Advanced or Metastatic Gastric or Esophageal or Gastro esophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib” (Sponsor:GlaxoSmithKline)

  • Protocol RI-01-002

    “A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma”

Fellowship at Indian Academy of Clinical Medicine (IACM) 

Memberships of oncology society

  • American Society of Clinical Oncology (ASCO) 
  • European Society of Medical Oncology (ESMO) 
  • Indian Academy of Cancer Research (IACR) 
  • European Association for Cancer Research (EACR) 
  • Indian Society of Medical and Pediatric Oncology (ISMPO) 
  • Cooperative Trials Group for Neuro-Oncology (COGNO) 
  • Indian Society of Neuro-Oncology (ISNO) 
  • International CML foundation (iCMLf) 
  • Society for Immunotherapy of Cancer (SITC) 
  • National Academy of Medical Sciences (NAMS) 
  • Association of Physicians of India (API) 
  • Indian Academy of Clinical Medicine (IACM) 
  • Equator Network – CONSORT 2010 reporting guidelines - Oxford, UK, 2010.
  • Randomized Controlled Trials – Oxford, UK, 2010
  • Statistics for Health Research – Oxford, UK, 2010

Dr. Wesley M. Jose joined Amrita Institute of Medical Sciences in April 2008. He currently serves as Professor at the Department of Medical Oncology and Hematology at Amrita Institute.
Dr. Wesley did his medical training from Christian Medical College and Hospital, Ludhiana, Punjab. Prior to joining Amrita, he worked as an Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana.
His core research interests lie in Neuro-oncology. He is an academician. He has presented several scientific papers and continues to be an invited faculty for various oncology conferences.
His primary clinical practice areas include: - Breast Cancer, Brain Tumors (Ault and Pediatric), Gastrointestinal malignancies, Multiple Myeloma, Lymphoma and Pediatric solid cancers.

  • Medical Training from Christian Medical College and Hospital, Ludhiana, Punjab  

    ADDITIONAL TRAINING 
  • Equator Network – CONSORT 2010 reporting guidelines - Oxford, UK, 2010. 
  • Randomized Controlled Trials – Oxford, UK, 2010 
  • Statistics for Health Research – Oxford, UK, 2010 
     

Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana .

  • Breast Cancer 
  • Brain Tumors (Ault and Pediatric) 
  • Gastrointestinal malignancies 
  • Multiple Myeloma 
  • Lymphoma and Pediatric solid cancers

  • RI-02-003

    Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukaemia (CLL) in Routine Clinical Practice

  • LRP/LNP3794/2016/006

    A Phase II/III Pivotal, Open-label, Randomized, 3 Arm Study to Assess the Efficacy of Lupin’s Molecule Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer as Second Line Therapy

  • CLDK378A2301

    A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Protocol No. 476-13

    A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Protocol No. - CDP/03/07

    "A randomized, multi-center, open label study to evaluate the efficacy and safety of Peg G-CSF as compared to Grafeel® in the prophylaxis of severe neutropenia in cancer patients receiving cytotoxic chemotherapy". (Sponsor: Dr. Reddy's Laboratories).

  • Protocol No. - MK-0683-088

    "An international, Multi-center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma". (Sponsor: Merck & Co Inc.)

  • Protocol No. - MORAb-003-004

    "A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety Weekly Farletuzmab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum sensitive Ovarian Cancer in First Relapse" (Sponsor: Morphotek Inc.).

  • Protocol No: EGF 110656

    "A Phase III Study of ERBB2 Positive Advanced or Metastatic Gastric or Esophageal or Gastro esophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib” (Sponsor:GlaxoSmithKline)

  • Protocol RI-01-002

    “A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma”

Fellowship at Indian Academy of Clinical Medicine (IACM) 

Memberships of oncology society

  • American Society of Clinical Oncology (ASCO) 
  • European Society of Medical Oncology (ESMO) 
  • Indian Academy of Cancer Research (IACR) 
  • European Association for Cancer Research (EACR) 
  • Indian Society of Medical and Pediatric Oncology (ISMPO) 
  • Cooperative Trials Group for Neuro-Oncology (COGNO) 
  • Indian Society of Neuro-Oncology (ISNO) 
  • International CML foundation (iCMLf) 
  • Society for Immunotherapy of Cancer (SITC) 
  • National Academy of Medical Sciences (NAMS) 
  • Association of Physicians of India (API) 
  • Indian Academy of Clinical Medicine (IACM) 

  • Equator Network – CONSORT 2010 reporting guidelines - Oxford, UK, 2010.
  • Randomized Controlled Trials – Oxford, UK, 2010
  • Statistics for Health Research – Oxford, UK, 2010